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ABSTRACT 
Nitric oxide (NO) has been shown to possess many Anti-inflammatory effects. Ascorbic 
acid which is naturally present in human body is known to react with S-nitrosothiols 
(RSNO) directly to reduce RSNO to NO and produce free thiol groups, if present in more 
than millimolar concentration. Higher concentration of ascorbic acid is required because 
the reduction of RSNO is not caused by ascorbate instead, but instead a decomposed 
product of ascorbic acid. S-Nitroso-N-Acetylpenicillamine is used as an NO donor. An 
HPLC method is used for determination of the degradation product of ascorbic acid and 
simultaneously identifying the compound responsible for NO production from RSNO by 
running the compound through Nitric Oxide Analyzer. Once the compound is identified it 
has a potential medical use for NO production. For example, it could provide a means that 
initiates RSNO decomposition in polymeric biomaterials. Thus, increasing the 
functionality of the medical device coated with such materials and preventing thrombus 
formation
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1. INTRODUCTION  
   With the increasing size of the population and the increasing multitude of illnesses 
such as diabetic, cardiovascular and neurological disorders which cannot be mitigated 
alone with medications, there is an increasing demand for implantable devices  
[1]. Over the last 60 year’s implantable devices have undergone a significant 
transformation becoming a valuable tool for monitoring and measuring physiological 
conditions. Success of these devices has heavily relied on the development of electronic 
technologies capable of interfacing with living tissues and organs at the micro and 
nanoscale level [2]. With increased in vivo stability, miniaturization along with some other 
parameters has led to the development of implantable electronic devices, such as sensors, 
cardiac pacemakers, implantable cardioverter defibrillators, cochlear implant, and bone 
stimulator, to name a few. These devices encompass a wide range of duration of intended 
use, level of invasiveness and device complexity. For example, needle-type glucose 
sensors are placed in subcutaneous tissue and intended to monitor glucose levels in 
interstitial fluid that is related to blood glucose levels. Another example are prosthetic knee 
implants which are intended to be imbedded in body within the patient and restore 
physiological function of the knee joint for 10 years.  
   Halperin et al. report that over 25 million US citizens are reliant on implantable 
medical devices for life-critical functions [3]. Despite of substantial innovations in the 
fabrication and application of implantable biomedical systems since the first implantable 
heart pacemaker of 1958, the modern implants patient is still faced with several challenges. 
Long-term reliability of the device is extremely important considering the high cost and 
time associated with surgical implantation along with patient recovery. The location of the 
implant space is a chemically harsh environment, where the surface of the implant will be 
continuously attacked by the highly conductive and corrosive physiological medium which 
also carries a variety of biochemically reactive organic molecules and metabolically active 
cells. The drive towards small, light, and flexible devices may affect the mechanical 
robustness of implants. The ensuing in vivo degradation and loss of integrity may be 
detrimental to the performance of the device, potentially leading to the device failure. 
Studies to improve the quality and design of both intravascular and subcutaneous sensors 
has been carried out since early1960s [4]. Only a handful of sensors have succeeded in the 
in vivo environment, with most failures due to the unpredictable performance resulting 
from the robust and dynamic biological response mounted by the body in response to the 
foreign device within the physiological system.   
 
   Achieving biocompatibility is a complex matter due to the dynamic host response 
to the synthetic and organic material used for device production. The host response must 
be balanced with the intended life time of a device and what is required of the device for 
appropriate functionality within the body. Focusing on the specific case of implanted 
sensors, one of the solutions under investigation is using a biodegradable material for 
fabrication of device which will allow controlled dissociation over time. Degradation 
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products will cause minimal toxic response and are removed from the implantation site by 
normal metabolic activity [5].   
One such example of biodegradable materials is using Magnesium based alloys. Stent 
used in cardiovascular application can be made from magnesium alloy. It has many 
advantages i.e. high biocompatibility (Mg is present in the body and will not be recognized 
as foreign material) , Alloy’s element are dissolved in the human body (no toxic waste), 
not visible be X-ray or CT scan (no artifacts)  . However, they do have some limitations 
like low corrosion resistant and suboptimal biocompatibility. Coating technology is one of 
the leading approach used to overcome these problems. Coatings on Mg-based stents can 
vary from metal and inorganic coatings to biodegradable coatings. Among these, 
biodegradable polymer coatings with drug-eluting features might be a better choice 
because of their advanced biocompatibility and capability to reduce late restenosis 
compared with other coatings. Developing implantable electronic device with 
biodegradable, non-toxic electronic materials on a such a small scale is difficult. A 
combination of robust and reliable electronics with a bio resorbable polymer platform 
offers both the flexibility of the device and sufficient bulk degradation that the immune 
response to the remaining material is minimal. For the technology to be clinically implanted 
certain challenges such as controlling degradation kinetics and biocompatibility of the 
device should be addressed. A review of the major issues that are involved in biological 
response to implanted devices follows, beginning with the risk of infection associated with 
implanted devices, the tissue response toward implanted devices, and coagulation inspired 
by implanted devices. By examining these separate processes, potential solutions to 
overcoming the host response to implanted devices can be developed.  
1.1. IMPLANT ASSOCIATED INFECTIONS  
  
Implantable devices have undergone a significant development due to the advancement 
in packaging designed to protect the indwelling device from hash physiological 
environment. Nonetheless, the risk of infections resulting from bacteria adhering to the 
implant is significant in terms of both morbidity and mortality of the patient and high costs 
associated with treating these device-associated infections. The highly invasive nature of 
the surgical procedure along with the health condition and inadequate immune response 
from the patient contribute to the causes of implant associated infection. Depending upon 
the severity of the infection treatment may involve localized antibiotic therapy to complete 
removal of infected implant. The incidence of infections associated with cardiac pacemaker 
implant ranges from 1%–19%, with 7%– 8% attributed to contamination during laboratory 
handling or the event of implantation [7]. Typically, the pre- and post-operative pathways 
are the most common pathways of biomaterial associated infection. If a patient is suffering 
from diabetic disease or using anti-inflammatory medication like corticosteroids and other 
immunosuppressive drugs may slow down surgical site healing and patient recovery, 
making the host more susceptible to developing an infection [8]. In addition, pathogens, 
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can originate elsewhere in the body and spreading to the implant site via blood, this route 
of infection is particularly important for devices that are in contact with the blood.  
  The physiochemical properties of the implanted surface render them susceptible for 
colonization by bacteria. The non-living nature of the implant surface means that it does 
not respond to the presence of bacteria nor does it produce chemical signals to notify the 
surrounding tissues of the imminent danger. Certain combination of surface properties can 
be employed to mitigate the host response to a certain level, but these modifications are 
helpless against bacterial cells that manage to adhere to implant surfaces. Furthermore, 
bacterial cells that adhere to implant surfaces release a significant amount of extracellular 
matrix to form a biofilm around the implant. In this biofilm state, they are protected from 
the host response and are not susceptible to systemic antibiotics. Hence, there has been 
more emphasis on developing surfaces capable of both preventing the bacterial adhesion 
and replication, and eliminating attached bacteria by releasing antibacterial drugs. The drug 
eluting property can be imparted onto the implanted module via encapsulation or surface 
modification. In addition to traditional antibiotics, a range of alternative antimicrobial 
agents have been considered, including silver ions, nitric oxide, bioactive antibodies, and 
other bactericidal compounds [9,10].  
1.2. HOST RESPONSE TO FOREIGN MATERIALS 
INFLAMMATION 
Inflammation and Coagulation are two major factors that significantly impact the 
function of the implanted device. When the properties of the surface materials are not 
properly matched with the characteristics of the surrounding tissues and cells the longterm 
utilization of the material may not be successful [11]. Surfaces of the implants may be 
contaminated by bacteria or bacterial cells which induces an inflammatory response. The 
physical presence of the implant, e.g., pressure it exudes onto the surrounding tissues and 
organs, can also trigger inflammatory mechanisms where affected cells release a host of 
chemical signalling molecules. Surgical intervention for introducing the implant triggers a 
pro-inflammatory response which delays the tissue healing. After the implant is exposed 
to chemically harsh environment, to the implant may begin to degrade as a result of this 
cell-mediated inflammatory response. Furthermore, the loosening of the implant has been 
linked to the increased incidence of inflammations, complications, and less successful 
functional performance of the implant.  
  Device implantation and associated tissue injury triggers a cascade of inflammatory 
and wound healing responses. The inflammatory response is comprised of two stages: acute 
and chronic phases. The initial acute phase lasts from hours to days. The acute phase is 
mostly responsible for cleaning the wounded site and provisional matrix formation. Vessels 
dilate and excess blood flows into the injury site. Numerous blood and tissue proteins such 
as cytokines and growth factors are released, and leukocytes adhere to the endothelium of 
the blood vessels and infiltrate the injury site.  
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Monocytes are then called into the site and these differentiate into macrophages [12]. 
Persistent inflammatory stimuli without resolution, such as the continual presence of the 
biomaterial/medical device, lead to chronic inflammation. Chronic inflammation is 
histologically less uniform when compared to acute inflammation, and the wound healing 
response is generally dependent on the size and/or degree of injury. This phase is generally 
characterized by the presence of monocytes, macrophages, and lymphocytes, as well as the 
proliferation of blood vessels and connective tissue to restructure the affected area. The 
formation of blood vessels is essential to wound healing, supplying necessary nutrients. 
Eventually, the granulation tissue is replaced by an extracellular matrix (ECM). The ECM 
acts not only as a physical scaffold but also as a crucial modulator of the biological 
processes, including differentiation, development regeneration, repair, as well tumor 
progression [13]. The end stage of the foreign body response involves walling off the 
implant by a vascular and collagenous fibrous capsule that is typically 50–200 µm in 
thickness. This fibrous wall confines the implant and consequently prevents it from 
interacting with the surrounding tissue.   
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Figure 1.1 Sequence of events involved in the foreign body response to an 
implantable device.  
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1.2.1 COAGULATION RESPONSE TO FOREIGN 
MATERIALS  
   Intravascular implants offer more advantage for patience care and improving the 
life style of the individual. However, they do face some major issues like size limitations 
and biocompatibility. Sensors not only have to be smaller in size but also must function 
fully in the presence of blood and the coagulation cascade.   
    Implantable devices as they come in contact with the blood, this will activate the 
coagulation cascade [14]. The end result of this response is a device coated with the 
provisional matrix that is a blood clot which contains metabolically active cells. This 
encapsulation can deeply affect the functionality of the sensor and resulting embolism risks 
for the patient of the blood clot breaks apart and travels to other locations within the 
vasculature [15].  
  Most common example of implant being encapsulated with calcium deposits are 
heart valves. Calcific deposits are seen on the heart valves within 3 years of 
postimplantation. It occurs due to chemical interaction within the aldehyde groups 
phospholipids and circulating calcium ions, immunological response. Calcification often 
starts at the commissure and the basal area of the cusp. Calcification can lead to stenosis 
due to cusp stiffening and regurgitation or incompetence, due to associated cusp tears. 
Occasionally, calcific deposits on the surface of the cusps may embolize to distant sites.  
    The blood coagulation cascade is can be initiated by either the intrinsic pathway or 
the extrinsic pathway. Details of the intrinsic cascade are shown in Figure 1 Briefly, 
Initially, proteins adsorb on the surface of the sensor immediately upon implantation. The 
composition of the blood bound proteins varies and change over the course. Composition 
of proteins adsorbed on to the surface depends on the Vroman effect and the nature of the 
implant (i.e. type of surface, curves, smooth etc.).  Next platelet bound to these surface 
proteins via expression of adhesion receptors (e.g. glycoprotein IIb/IIIa which binds to the 
plasma ligand fibrinogen), contractile protein within the platelets tighten and the platelet 
flattens to form “false-legs” or pseudopodia [16]. This enables them to cover more surface, 
at the same time contraction causes degranulation of platelets. Degranulation releases a 
number of chemicals including ADP and thromboxane A2. These chemicals are potent 
platelet activators, thus attracting nearby platelets to the surface increasing the platelet 
adhesion and aggregation. In the end, the implant surface will be coated with stabilized 
activated platelet that binds with factor V to activate local thrombin. Thrombin once 
formed interacts with fibrinogen to form a mesh of fibrin around the implant. Fibrin 
interacts with platelets to Breaking of the thrombi and freely entering the circulating blood 
causes poses a serious threat. Only presence of a monolayer of thrombus will not affect the 
sensor or make it less responsive to the analyte. 
 However, thrombus formed with the metabolically active cells creates a different local 
environment which is different compared to the bulk blood. Thus, misleading the sensor 
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from analyzing the actual condition of the analyte (i.e. bulk blood). Additionally, there will 
reduced blood flow to the implanted area i.e. vasoconstriction which will change the local 
form a consolidated structure around the implant which can entrap circulating cells. Thus, 
aggregated platelets, cells and fibrin thread forms a thrombus known as blood clot. Shown 
in Figure 1.3  
   Breaking of the thrombus and fragments freely entering the circulating blood poses a 
serious threat. Thrombus once circulating freely into the blood stream can block any artery 
or vein leading to a blood clot, hence it is as serious threat. Only presence of a monolayer 
of thrombus will not affect the sensor or make it less responsive to the analyte. However, 
thrombus formed with the metabolically active cells creates a different local environment 
which is different compared to the bulk blood. Thus, misleading the sensor to from 
analyzing the actual condition of the analyte (i.e. bulk blood). Additionally, there will 
reduced blood flow to the implanted area i.e. vasoconstriction which will change the local 
metabolic activity, thus affecting the sensor data even further by misinterpreting the 
condition. It is clear that understating this coagulation cascade and stopping it in its 
pathway is extremely important for full functionality of the sensor  
  
  
Figure 1.2 Intrinsic Coagulation cascade initiated by blood contact with foreign materials 
implanted within the vasculature. Dotted lines show potential pathways of positive 
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feedback mechanism. Typical end product of cascade is the formation of a thrombus on 
the exposed surface of the implant. Adapted from Dee [17]  
Form a consolidated structure around the implant which can entrap circulating 
cells.  
Thus, aggregated platelets, cells and fibrin thread forms a thrombus known as 
blood clot. Shown in Figure 1.3  
  
  
Figure 1.3 Depiction of exposed surface of an implanted sensor in contact with the blood. 
Protein adhesion facilitates platelet adhesion and activation which initiates intrinsic 
coagulation cascade leading to the thrombus formation. Adapted from Frost [5]  
CONTROL POINTS IN COAGULATION CASCADE  
• Coagulation cascade is a complex system with both feedback and feedforward loop. 
Controlling this complex process can eventually yield us control over implantable 
sensor functionality and improving the lifetime of the sensor. Steps within the cascade 
which are vital to the process are listed below (Adapted from Tissue-Biomaterials 
Interactions. 2002: John Wiley &Sons [17])  
• Calcium: - Calcium is required at each step of the coagulation cascade, except for the 
factor XII and XI activation. Without calcium blood with not clot.  
• Thrombin: - Thrombin is major component of the feedback loop, controlling the 
availability of thrombin and its reactivity a major portion of the cascade can be 
controlled  
• Clotting factors: - Clotting factors are the key to the coagulation cascade. Controlling 
few clotting factors like Factor X can yield a potential control point because it is a 
common link between the pathways.  
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• Platelets contribution: - Platelets can be viewed as a surface catalyst for coagulation 
process. Platelets are the first thing to adhere to the foreign body, initiating platelet 
aggregation.  
 1.2.2 EXTRINIC COAGULATION CASCADE  
Activated factor Xa is the site at which the intrinsic and extrinsic coagulation 
cascades converge. The extrinsic pathway is initiated at the site of injury in response to the 
release of tissue factor (factor III) and thus, is also known as the tissue factor pathway. 
Tissue factor is a cofactor in the factor VIIa-catalyzed activation of factor X. Factor VIIa, 
a gla residue containing serine protease, cleaves factor X to factor Xa in a manner identical 
to that of factor IXa of the intrinsic pathway. The activation of factor VII occurs through 
the action of thrombin or factor Xa. The ability of factor Xa to activate factor VII creates 
a link between the intrinsic and extrinsic pathways. An additional link between the two 
pathways exists through the ability of tissue factor and factor VIIa to activate factor IX. 
The formation of complex between factor VIIa and tissue factor is believed to be a principal 
step in the overall clotting cascade. Evidence for this stems from the fact that persons with 
hereditary deficiencies in the components of the contact phase of the intrinsic pathway do 
not exhibit clotting problems. A major mechanism for the inhibition of the extrinsic 
pathway occurs at the tissue factor-factor VIIa-Ca2+-Xa complex. The protein, lipoprotein-
associated coagulation inhibitor, LACI specifically binds to this complex. LACI is also 
referred to as extrinsic pathway inhibitor, EPI or tissue factor pathway inhibitor, TFPI and 
was formerly named anticonvertin. LACI is composed of 3 tandem protease inhibitor 
domains. Domain 1 binds to factor Xa and domain 2 binds to factor VIIa only in the 
presence of factor Xa.   
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Figure 1.4 the extrinsic coagulation pathway. Reaction products are underlined; the 
dashed lines denote potential feedback loops. After the production of thrombin has been 
achieved, the reactions outlined in  
  
1.3 COPING UP WITH HOST COAGULATION RESPONSE  
    The most common method to prevent coagulation in patients with implanted 
devices is the use of anticoagulants. The most widely used anticoagulant is heparin. 
Heparin inactivates thrombi in the clotting process, this stops the formation of fibrin hence 
prevent blood clot. Heparin is also used to treat blood clots formed abnormally inside the 
blood vessel. Heparin is administrated both orally and intravascularly. Heparin interacts 
with antithrombin III and enhances its ability to inactive coagulation enzyme thrombin, 
which in turn prevents blood clot formations. It also affects other clotting factors like 
Factor Xa and IXa [18]. However, heparin may have several negative effects. Heparin can 
cause you to have bleeding episodes while you are using it and even several weeks after 
you stop using it. It also interacts with a number of plasma proteins which are not even 
involved in the coagulation cascade.  
  Studies have shown that plasma protein available for interaction with heparin may 
vary from person to person [19], thus heparin is only partially effective at inhibiting the 
thrombus formation on the implanted device. Moreover, prolonged used of heparin can 
cause bleeding issues, for few weeks after the use. Extreme effects of heparin 
administration are bone loss by decreasing bone formation i.e. osteoporosis and reducing 
the platelet count [20] i.e. thrombocytopenia [21]. Many patients who have implanted 
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sensors in their body already have hemostatically compromised condition, using heparin 
may worsen their condition. Hence. the use of heparin to improve the biocompatibility is 
still under question.   
    It is clear that we cannot rely on the efficiency of the anticoagulants, there is a need 
for development of new techniques for passivating the host response. Techniques like 
development of polymer coating or outer membrane that could potentially passivate the 
implanted device to some extent of the host response. Number of approaches like naturally 
derived materials, diamond like carbon, hydrogels, topology treatments etc. were used [22]. 
Many of these materials showed good progress during in vitro study of cell or protein 
adhesion, but in vivo study some resistance to host response. Ultimately, body’s defense 
will overcome the static surface and initiate a host response which will affect the sensor 
performance.  
1.4 SOLUTION TO OVERCOME FOREIGN BODY RESPONSE 
Properties of biomaterial surface influences how it will react with proteins once it 
comes in contact with the blood. Blood comprises of about 150 different type of proteins. 
Surface properties is usually grouped into three categories: geometric, chemical, and 
electrical. Thumb rule being greater the surface area more possible sites for protein 
interaction. For example, surface with grooves and pores will have greater surface are 
compared to smooth surfaces. So, grooves and pores should be avoided unless they are a 
part of the design. Also, surface features like the machine marks also provide additional 
site for protein interaction. So, the key is keeping the implant surface as simple as possible.  
  Chemical composition of the material will determine which functional species are 
available for interaction with biomolecules. The oxidized (passivated) surface of a metallic 
biomaterial exposes metal and oxygen ions. Similarly, ceramic, and some glass, surfaces 
comprise metal and nonmetal ions. A variety of functional species, such as amino, 
carbonyl, carboxyl, and aromatic groups, can be present on the surface of polymeric 
biomaterials. Depending on which species are exposed, biomolecules (or even particular 
regions of the molecule) may have different affinities for various surfaces. For example, 
hydrophobic surfaces tend to bind more protein as well as binding it more tenaciously.   
 Biomaterial surfaces are often in homogeneous. Patches, or domains, of different 
functionality can exist on biomaterial surfaces, and these patches can interact differently 
with biomolecules. For example, many metallic biomaterials contain at least two different 
phases, such as the a- and b-phases in Ti-6Al-4V. Not only can the different phases behave 
differently when interacting with biomolecules, but grain boundaries behave differently 
than do grain interiors. In polymers, segregation resulting from folding of macromolecular 
chains can give microstructural domains. Depending on the chemical species present 
within the various domains, proteins will have different affinities for the patches.  
Controlling this initial protein interaction on the surface of biomaterial can help 
dictate the entire foreign body response.  
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To overcome the limited in vivo functionality and longevity of implantable devices, 
some important approaches have been reported  
1.4.1 BIOCOMPATIBLE MATERIAL COATING  
The use of biocompatible materials for coating implantable devices is based on their 
ability to mask the underlying surface. Masking is achieved by producing a hydrophilic 
interface between the device surface and the tissue fluids, thereby minimizing tissue 
reactions induced by device implantation [23]. The formation of these biocompatible layers 
improves implantable device/host tissue interactions and consequently improves device 
functionality and life span  
Various natural, synthetic, and semisynthetic materials are currently utilized in the 
fabrication of implantable device coatings. Naturally occurring materials include (a) 
alginate, (b) chitosan, (c) collagen, (d) dextran, and (e) hyaluronan. These methods offer 
the advantage of being very similar to macromolecular substances that the biological 
environment is prepared to recognize and to deal with metabolically. On the other hand, 
serious disadvantages are (a) natural polymers are frequently immunogenic, (b) these 
polymers typically decompose or undergo pyrolytic modification at temperatures below 
their melting point, thereby precluding the convenience of high-temperature thermoplastic 
processing methods (such as melt extrusion) during the manufacturing of the implant, and 
(c) since they are derived from animal or plant sources, natural variability in 
macromolecular structure are expected. Numerous synthetic polymeric materials have been 
employed as coating materials, e.g., poly(lactic-acid) and poly (lactic co-glycolic acid) 
(PLGA) , poly(ethylene-glycol), 2-hydroxyethyl methacrylate , poly(ethylene glycol) 
(PEG) , and poly(vinyl-alcohol) (PVA). Knowledge of the physical and chemical 
properties of the polymer is a useful tool to rationalize the choice of the coating material.  
Quinin and et al developed [24] Photo-crosslinked copolymers of 2-hydroxyethyl 
methacrylate, poly (ethylene glycol) tetra-acrylate and ethylene dimethacrylate for 
improving biocompatibility of biosensors. They coated the copolymer created on the 
electrode of a glucose sensor and compared with a control electrode which did not have 
any copolymer coating. The explanted samples were evaluated using scanning electron 
microscopy. The control electrodes were highly encapsulated with fibrous material, while 
the copolymer-treated electrodes induced much less encapsulation. The results show this 
copolymer to be a candidate as a biocompatible coating for electrically wired 
oxidoreductase-based subcutaneous biosensors.  
1.4.2 ANGIOGENIC DRUGS  
  Biosensor functionality and longevity can be compromised by a biofouling 
response and the formation of an avascular fibrous capsule around the device that greatly 
decreases both the transport of analyte from the tissue to the sensor and the diffusion of 
reaction products from the sensor to surrounding. Therefore, controlling fibrotic 
encapsulation at the implant site would appear to be critical to achieve a functional and 
extended life-time biosensor in vivo. One approach to improve the analyte transport around 
 13 
the implant is the promotion of angiogenesis. This can be achieved by inducing new blood 
vessel formation in the vicinity of the sensor using growth factors such as the vascular 
endothelial growth factor (VEGF) [25]. It is noteworthy that well-vascularized tissue at the 
implant site is also critical for healing the trauma caused during implantation. Another 
issue associated with the use of corticosteroid drugs to treat the inflammation process is 
that these drugs also downregulate endogenous VEGF, thereby inhibiting angiogenesis. 
Accordingly, a two-pronged approach (control of inflammation and induction of 
angiogenesis) may be necessary.  
  Patil SD and et al developed [26] Dexamethasone-loaded poly(lactic-co-glycolic) 
acid microspheres/poly (vinyl alcohol) hydrogel composite coatings for inflammation 
control. Dexamethasone-loaded PLGA microspheres were prepared using a solvent 
evaporation technique. Composites were fabricated by dispersing microspheres in PVA 
solution and performing freeze-thaw cycling. Composites were implanted into 
subcutaneous tissue of rats. PLGA microsphere/PVA hydrogel composites eluting 
dexamethasone were successful in controlling negative tissue reactions at the sensortissue 
interface by reducing the level of inflammation-mediation cells to those observed in normal 
tissue.  
1.4.3 IMPLANTED POLYMERS  
Recent studies showed that active approach is much more effective than coated 
materials developed in the past. Worked done earlier on surface bound heparin [27] has 
been extended to materials which release heparin in vivo. Gutowaska et al. [28]. Developed 
thermosensitive polymer blends using Biomer/poly 
(Nisopropylacrylamide)/[poly(NiPAAm)]. This technique was based on temperature 
dependent swelling of the material. At room temperature, i.e., below the lower critical 
solution temperature (LCST) of poly (NiPAAm), the Biomer/(poly(NiPAAm) coatings are 
highly swollen. Swelling enables fast loading of hydrophilic macromolecules (e.g., 
heparin) into the coating by a solution sorption technique. At a body temperature, i.e., 
above the LCST of poly (NiPAAm) the coatings are in a de-swollen state and the absorbed 
macromolecules may be slowly released from a dense coating via a diffusion controlled 
mechanism. The results show that the heparin release from  
Biomer/poly(NiPAAm)-coated surfaces resulted in a significant reduction of thrombus 
formation on test surfaces in contact with venous blood as compared to control surfaces in 
vitro studies. However, considering the complexity of the in vivo environment, there is 
need for further study to access the efficacy of heparin releasing materials in improving the 
biocompatibility of the implanted sensors.  
Nitric Oxide (NO) is another potentially viable option to help control the coagulation 
cascade.NO has a diverse array of functions in vivo including help controlling the blood 
vessel tone and adhesion molecule expression. Nitric Oxide is also a potent inhibitor of 
platelet aggregation and activation [22,23], due to its role in stimulation calcium 
sequestration and inhibiting the synthesis of thromboxane A2 in platelet. NO is also 
involved in endothelium cell and smooth muscle cell proliferation; it has a direct role in 
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destruction of bacteria during phagocytosis by macrophages [24]. Vascular endothelium 
cells generate NO flux of 1.0-4.0*10-10 mol/cm2 min continuously [25]) has been their 
primary basis for the non-thrombogenic properties of the vascular endothelium, surface 
which elicits no host response despite constant contact with precursor molecules to the 
intrinsic coagulation cascade. Endogenous NO supply diffuses into the lumen of the blood 
vessels and smooth muscles cells that surrounds all the arteries where it plays an important 
role in preventing platelet activation in healthy blood vessels.  
 The innate physiological function of NO makes it a strong candidate for improving the 
biocompatibility of the implanted sensors. NO releasing sensors will be single handed 
capable of controlling the both platelet adhesion and activation along with minimizing 
vasocontraction. NO releasing subcutaneous implanted sensors will ensure increased blood 
flow to the sensor surface, increasing transfer of analyte and reducing bacterial infection. 
Half-life of NO in blood is 0.5-1.8ms [23], thus the NO generated will no create any 
systemic effects.  
1.5 NO RELEASING MATERIALS  
 The encouraging work in early NO studies led to serious efforts for creating NO 
releasing materials which has been ongoing for 20 years. Organic nitrites, metal complexes, 
nitrosamines, nitrosothiols and diazeniumdiolates are some of the potential candidates 
arising from the work. The diverse structures used for NO donors causes varied chemical 
reactions and NO-release kinetics [26], which can be used for controlling the dose of NO 
delivered.  
  There are two mechanisms from which NO can be generated from their donors, 1) 
exogenous NO release and 2) those which generate NO by decomposing endogenous NO 
donors.  
1.6 EXOGENOUS NO DONORS  
 Recently a class of NO donor’s diazeniumdiolates has getting much attention 
known as N-diazeniumdiolates, or “NONOates” as an exogenous NO donor. They produce 
predictable amount of NO and ease to prepare. NONOates generate NO spontaneously 
under physiological condition and stable at ambient temperature and can be covalently 
attached to polymer films [28,29]. Release of NO from NONOates is influenced by 
biological factors so no tolerance can be developed against it. The stability of N-
diazeniumdiolates depends on the concentration of the donor in material as well as pH 
temperature and/or structure of substrate. Study by Frost et al. [30] studied the performance 
of a Clarke-style amperometric oxygen-sensing catheter coated with a ~ 100µm layer of 
polymer covalently bonded to diazeniumdiolates. Results suggested that NO release 
through this technique greatly reduces thrombus formation. 
  RSNOs also known as S-nitrosothilos emerged as a potential candidate for exogenous NO 
release. There are three known mechanisms for NO generation from RSNOs: -  
• Metal ion i.e. copper mediated decomposition   
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• Ascorbate mediated decomposition  
• Photo-initiated decomposition [31]       
  
Light can be used as an ON/OFF switch to generate NO if decomposition via metal 
ions. Ascorbate mechanism is independent of light. Frost et al. developed a tri-layer silicon 
rubber (SR) film wherein one of the layer is blended with S-Nitroso-N-acetyl-
DLpenicillamine derivatized fumed silica was sandwiched between two layers of pure SR.  
Film showed photolytic NO generation without being sensitive to copper and ascorbate. 
NO generated was dependent on the intensity and duration of light it was exposed to. This 
points out that RSNOs with the help of a controllable light source could be used to anchor 
the NO generation on the surface of the implantable sensor.  
  
1.7 ENDOGENEOUS NO DONORS  
NO is generated naturally in mammalian body, NO precursors in the form of nitrites 
and RSNOs are present in the body in micro-molar concentration. Cu2+ metal ions along 
with other metals are known to cause reduce RSNOs to generate NO in aqueous solution 
[32]. Wu et al. developed polymeric coating with Cu0 particles which will slowly corrode 
to produce reactive ions to decompose RSNOs to produce NO [34].  These coatings were 
applied to catheters and tested in vivo showed positive results. However, few incidences 
showed that control and NO generating fiber showed thrombus formation, because of the 
low concentration of RSNOs in those animals.  
  
 16 
  
  
  
Figure 1.5 Clarke type amperometry intravascular sensor post-explanation. The region to 
the left with dotted lines shows the portion of the sensor which was placed within the 
vasculature. The sensor on the left incorporated NO releasing material sensor on the right 
was without modification  
  
1.8 BACKGROUND OF ASCORBIC ACID  
Ascorbic acid is an isolated nutrient which is part of vitamin C. Ascorbic acid can be 
normally found in human body. Recently studies on ascorbic acid has been increasing 
because of its ability to react with RSNOs and produce NO. Holmes et al. reported that 
ascorbic acid can interact directly with RSNOs if present in more than milli-molar 
concentration to produce NO. Preliminary evidence suggested that it is a decomposition 
product of ascorbate responsible foR the NO from nitrosotiols rather than high 
concentration of ascorbate. Higher concentration is required because the species 
responsible for the decomposition is not actually ascorbate. A partial decomposition 
pathway can be seen in Figure 4.  
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Frost and et.al. used S-Nitroso-N-acetyl-DL-penicillamine (SNAP) as NO donor and 
treated with both fresh ascorbate and decomposed ascorbate. Nitric oxide measured using 
via chemiluminescence using nitric oxide analyzer. Ascorbate was allowed to decompose 
naturally under ambient condition for 8 days. It showed that oxidized ascorbate releases 10 
times more NO than the fresh ascorbate. Seen in Figure 5. This shows clear evidence that 
it is actually a decomposition product of ascorbate than the ascorbate itself.  
 Depending on the decomposition pathway (Figure 4) they suspected the compound to 
be a four-carbon sugar Threose. They treated threose with SNAP to measure the amount 
of NO release. Results showed that only 50% of the threose was used, which states that 
clearly there is another decomposition product present in threose syrup which is 
responsible for NO release. Clearly a lot of work has to be done in identifying the actual 
product that causing it to release NO.  
1.9 STATEMENT OF PURPOSE  
 The extent to which host response can be controlled is directly proportional to the 
functionality of the implanted device. Controlled NO release from the implanted device is 
the key. Given that it is now know how different fluxes of NO generated will impact the 
host response at the tissue -material interface in the acute and chronic response, it cannot 
be known the best way to mitigate the host response using NO. Determining an ideal 
therapeutic flux of NO and then being able to deliver the needed amount will help fight 
against the host response tremendously.  
 Natural source of reducing agent along with naturally available NO donors could be 
instrumental in developing a new technique for NO release. Ascorbic acid is naturally 
present in human body and traces of S-nitrosoglutathione is been found in the form of 
proteins. The goal of this work is to identification of NO generating decomposition product 
of ascorbic acid. High performance Liquid Chromatography (HPLC) along with 
chemiluminescence (NO Analyzer) can be used for separating compound from 
decomposed ascorbate and measuring NO generated from it. Once the compounds are 
separated Mass Spectroscopy can be used to identify the compound.  
 To collect real time NO data from the HPLC separated compounds we need a 
device which is capable of providing a medium for the compounds to react and generate 
NO. A new 3-D printed device needed to be created for integrating HPLC with NO analyzer 
(Discussed in detail in chapter 2). Thus a 3-D printed device is able to serve as a medium 
for HPLC separated compound to react with RSNOs to generate NO. 
If the active compound identified is non-toxic and can be stabilized, it could prove as 
a novel method too initial RSNOs decomposition in polymeric material or endogenously 
from RSNOs present in the body. E.g. Medical grade polyurethane doped with the reducing 
agent can be formulated in such a way that when it comes in contact with the blood the 
active agent leaches from the material decomposing circulating nitrosothiols.  
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Figure 1.6 Decomposition pathway of ascorbic acid to the reducing sugar threose in neutral 
pH  
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Figure 1.7 Final concentration of oxidized ascorbate and fresh ascorbate were 2.5 mM after 
the first inject and 5.0 mM after the second injection.  
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2. ASCORBIC ACID  
 Ascorbic acid or vitamin C is a small molecule nutrient that is essential for normal 
functioning in the human body (see Figure 2.1). Among its many functions, it acts as an 
antiscorbutic agent (curing scurvy) and is a cofactor in a variety of enzymatic process [1]. 
Ascorbic acid is also known for its antioxidant property in both in vitro and in vivo. The 
first metabolic decomposition product of ascorbic acid is its conversion to dehydroascorbic 
acid (DHA); this process is reversible which is suspected to be responsible for antioxidant 
properties of ascorbic acid. DHA will irreversibly degraded to 2,3-diketogulonic acid and 
then to over 50 species containing five or fewer carbons [2]. The complete pathway of 
degradation is yet unknown. Ascorbic acid is also known to react with RSNOs to produce 
NO [3]. Much work has been done on studying degradation products of ascorbic acid and 
their functions in the body, but this complex pathway is far from being understood. Gaston 
Vernin, et al. studied thermal degradation of ascorbic acid at 3000 C yielded furan 
derivatives and ∝, 𝛽𝛽-unsaturated cyclic ketones with a fivemembered ring [4]. Since 
ascorbic acid is a part of our daily food cycle it makes it all the more important to identify 
its decomposition product triggering NO release, since it is naturally present in our body.  
 
Figure 2.1 The structure of ascorbic acid.  
 
  There are three known mechanics of NO generation from S-nitrosothiols (RSNOs) 
[5]. Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then Cu+ 
reduces RSNOs to NO and produces disulfide bonds. Common species used to reduce Cu2+ 
to Cu+ are free thiolate ions present and ascorbic acid. Ascorbic acid itself has been reported 
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to directly interact with RSNOs when it is present at greater than millimolar concentrations 
to reduce RSNO to NO and produce free thiol groups. The mechanism of this reaction is 
not known [6]. The third known mechanism of NO generation from RSNOs is by means 
of photoinitiation.  
  Dasgupta and Smith published a study entitled “Kinetics and Mechanism of the  
Decomposition of S-Nitrosoglutathione (Type of RSNOs) by Ascorbic Acid and Copper  
Ions” [6]. They state that S-nitrosothiols severs as a good source of NO mainly due to the 
ease of cleavage of S-N bond which consequently produces NO. The reductive 
decomposition of the specific RSNO, S-nitrosoglutathione (GSNO) by ascorbic acid 
produced NO which was monitored both electrochemically and spectrophotometrically. 
The rate of reaction and NO release occurs in both an ascorbate concentration and a pH 
dependent manner. Where ascorbate is required in greater than millimolar levels and little 
to no decomposition at low pH (below 5.5). Reductive decomposition of GSNO by 
ascorbate in an aqueous solution was carried out in the presence of EDTA to suppress any 
Cu2+ present.  
  Dasgupta and Smith proved that GSNO decomposed with a liner dependence on 
the concentration of ascorbate from 10-55mM. In their analysis.  They could only account 
for the 90% of ascorbate used initially when combining total ascorbate and DHA present 
initially, claiming that the lost 10% was probably due to “analytical error”. This suggests 
that ascorbic acid decomposes into different or additional products and it is possible that 
one of these products is an active agent that is responsible for the release of NO from 
RSNOs.  (i.e., more favorable redox potential and/or kinetics of electron transfer to react 
directly with RSNOs).  
  Figure 2.2 shows NO generated from 0.227 mM SNAP solutions in PBS at pH 7.4 
upon the addition of fresh ascorbate and the addition of the same amount of oxidized 
ascorbate from the same solution after 8 d of decomposition under ambient conditions 
using chemiluminescenc detection [7]. After the first injection of ascorbate or oxidized 
ascorbate, the final concentration of ascorbate was 2.5 mM and 5 mM after the second 
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injections. Clearly there is more NO generated from the oxidized ascorbate than from the 
fresh ascorbate, by nearly a factor of 10 
  
  
Figure 2.2 Comparison of NO generated from 0.227 mM SNAP solution in PBS at pH 7.4  
[7].  
None of the work published to date has been able to identify the mechanism of 
ascorbic acid to directly decompose RSNOs nor have decomposition products of ascorbate 
been investigated as potential species that release NO from them. Correctly identifying the 
product or products that may be responsible for RSNO decomposition may provide us with 
new candidate material(s) for coatings on the implanted device and may also improve their 
performance in vivo and help mitigate host response. This study has developed a new 
experimental method to help separate the decomposition products which are responsible 
for NO release from the well-known RSNO, S-nitroso-Nacetylpenicillamine (SNAP).  
    As previously discussed in chapter 1 the amount of NO generated from 
decomposed ascorbic acid is more than that produced by fresh ascorbic acid. This clearly 
indicates that it is not actually ascorbic acid but one its decomposition product which leads 
to increased production of NO.  
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2.1 WORKFLOW OF THE EXPERIMENTS  
 The general idea is to provide clear evidence that one or more of the products in 
decomposed ascorbic acid is capable of generating NO from a standard RSNO solution. 
Fresh ascorbate was allowed to decompose and then the products were separated with 
reversed-phase HPLC. UV-VIS spectroscopy of known standards of both ascorbic acid and 
dehydroascorbic acid were used for determining peak absorption wavelength of these 
compounds A diode array detector that recorded full UV-Vis spectra was used with the 
HPLC system to achieve detection of the components present in the decomposed ascorbate 
solution. Once peaks of the decomposed ascorbate were obtained along with the retention 
time, spectral analysis was carried to track how the absorbance changes over time. This 
helped further confirm the presence of more than one compound in decomposed ascorbic 
acid. Once the separation was successful, the HPLC eluent was merged with a stream of 
S-nitroso-N-actylpenicillamine (SNAP) and the headspace was sampled to detect the 
production of NO. The compounds separated via HPLC that generated NO were then 
analyzed with mass spectrometry to identify candidate compounds that are responsible for 
NO generation.   
2.2 MATERIALS AND METHODS  
    L- (+)-Ascorbic Acid used for experiments was purchased from J.T BAKER. 20 ml 
disposable scintillation vials were used for storage of ascorbic acid samples; Deionized 
water was used as base solvent for preparation of ascorbic acid. Ascorbic acid of varying 
concentration was prepared ranging from 1 M to 100 mM depending upon the needs of 
the experiments. Ascorbic acid was allowed to decompose naturally for 8 days under 
ambient conditions in the presence of normal sunlight at pH 5.5, decomposed ascorbic acid 
pH was measured to be 4.5. A PerkinEmler Lambda 35 UV/VIS Spectrometer was used to 
read solution absorbances. Disposable spectrophotometer cuvettes purchased from VWR 
International (Randor, PA) were used. A PerkinELmer HPLC systems consisted of Series 
200 Vacuum Degasser, Series 200 pump, Series 200  
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EP Diode Array Detector and a 20 L injection loopwas used. The column used for HPLC 
separation was C18 (5 μm, 10 cm x 3.2 mm) purchased from ES Industries. C18 is 
combination of hydrophobic and silanophilic mechanisms. C18 packings are highly 
retentive for polar and non-polar compounds. Two mobile phase solvents were used: 
Mobile Phase A – HPLC grade Methanol + 0.1% Trifluoroacetic acid, Mobile phase B – 
Deionized water + 0.1% Trifluoroacetic acid.. Sievers 280i Nitric Oxide Analyzer was used 
for the direct detection of NO via chemiluminecnce detection.  The syringe pump used for 
controlled release of RSNOs was purchased from Kent Scientific (Farmingdale, NY).   
2.2.1 SNAP SYNTHESIS  
  N-Acetyl-DL-penicillamine, sodium nitrite (NaNO2) and methanol were obtained 
from Sigma (St.Louis, MO). Sulfuric acid (H2SO4) and hydrochloric acid (HCl) were 
obtained from Fisher Scientific (Pittsburgh, PA). SNAP crystals were made using the 
method of Field,136 et. al [7]. One-hundred mg of N-acetyl-DL-penicillamine, 5 mL of 1 
M NaNO2, 10 mL of methanol, 10 mL of 1 M HCl and 0.5 mL of H2SO4 were combined.  
 
A very dark green solution developed nearly instantly. The solution was stirred for ~40 
min. The volume of the solution was reduced by blowing nitrogen gas over the solution 
and the flask was ice cooled. Green crystals were collected via suction filtration and 
washed with water. Crystals were re-crystalized from methanol and allowed to air dry.  
  2.2.2 SNAP-PDMS SYNTHESIS   
  Detailed synthesis of this materials has been described elsewhere [7], briefly 1.6 g 
of hydroxy-terminated PDMS was mixed with 0.3 g of 3-aminopropyl trimethoxysilane, 
2.4 mg of dibutyltindilaurate and 8 mL of toluene. The solution was stirred for 24 h to 
crosslink the PDMS. A self-protected thiolactone was synthesized according to the method 
by Moynihan [8]. Fifty milligrams of this thiolactone was then mixed with 1 mL toluene 
followed by 2 mL other crosslinked PDMS. The solution was stirred for an additional 24 
h to allow the thiol-containing compound to react with the primary amine groups present 
on the cross-linking agent. The resultant free thiol was then converted to the corresponding 
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RSNO by reaction with t-butylnitrite, producing the characteristic emerald green SNAP-
PDMS.  
    All the experiments were carried out in two sets, first it was performed on fresh 
ascorbic acid and then repeated on decomposed ascorbic acid. For verifying the 
consistency of the results experiments was repeated at least three times. In-order to separate 
the compounds using HPLC there was need to identify the wavelength window of fresh 
and decomposed ascorbic acid. This wavelength window will help setup the detection limit 
for both compounds while the separation is being performed. So the first setup is to identify 
the absorption wavelength of both the compounds using UV-VIS spectroscopy.  
2.2.3 UV-VIS SPECTROSCOPY   
  To establish the detection limit of the HPLC system toward ascorbic acid, UVVIS 
Spectroscopy was used. UV-VIS Spectroscopy works on Beer-Lambert law. Ascorbic acid 
and decomposed ascorbic acid sample was prepared and diluted to 1 micro-molar 
concentration for accuracy. Since de-ionized water was used for preparation of both the 
samples, it was used as a base sample for the experiment. Since the concentration of the 
samples are known UV-VIS Spectroscopy helps to identify the absorption wavelength of 
the samples.  
2.2.4 NO ANALYZER   
  To integrate the complex system and get a real-time analysis of the amount of NO 
released a medium was required. 3-D Printed device was developed to act as a medium to 
integrate multiple system together details of the device are describe in detail in the latter 
half of the chapter. Initially NO analyzer was used to track the amount of NO released 
when fresh ascorbic acid and decomposed ascorbic acid when treated with SNAP using the 
3-D Printed device. This data clearly indicates that decomposed ascorbic acid produces 
more NO than fresh ascorbic acid. (Figure 2.11 provides sufficient evidence). Left and the 
right opening of the 3-D printed device receives input from syringe pump i.e. SNAP and 
Fresh/Decomposed ascorbic acid. Central opening is connected to the NO analyzer which 
collected the NO reading data across the gas permeable membrane. Graph below represents 
NO analyzer data.  
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  Once HPLC is used for separation of decomposed ascorbic acid, NO analyzer is 
used again to repeat the same procedure as above to track the amount of NO released. 3D 
printed device receives one input from syringe pump i.e. SNAP and the other input from 
HPLC i.e. separated compounds. This provides real time data and a direct comparison 
which compound produces more NO.  
  
2.3 RESULTS AND DISCUSSION  
2.3.1 UV/VIS DATA  
    UV/VIS spectroscopy was performed on both fresh and decomposed ascorbic acid. 
Ascorbic acid (1mM) and decomposed ascorbic acid (1mM) were diluted to 1 M 
concentration for higher resolution and more accurate data. Since deionized water was used 
as a base solvent for preparing both compounds, hence it was also used a standard reference 
for both the experiments. Detection window for UV-VIS is between 200-700 nm  
 Figure 2.3 shows a representative UV/VIS spectrum for fresh ascorbic acid and 
decomposed ascorbic acid. Data suggests that peak absorption wavelength of ascorbic acid 
is 263nm which is consistent with the literature. Several peaks with consistent change of 
absorbance can be seen in the figure. Additionally, the absorbance of the ascorbic acid peak 
at 263nm is reduced in intensity from 0.56 to 0.25, indicating a loss of compound. This 
confirms that the ascorbic acid did indeed decompose and other compounds are present in 
the solution. These peaks range from 200 – 400 nm. This information is vital because it 
will help setup up the detection range for HPLC while physically separating these 
compounds.  
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Figure 2.3 UV/VIS data for fresh ascorbic acid sample and Decomposed ascorbic was 
allowed to decompose in natural light and ambient temperature for 8 days, acid with 1 
micro-molar concentration.  
2.3.2 HPLC DATA  
    Because Figures 2.5 and 2.6 clearly indicate that some product in the decomposed 
ascorbate solution is initiating release of NO, reversed phase HPLC was used to separation 
the decomposed ascorbic acid in an effort to allow the identification of which component(s) 
were responsible for this NO release. In this technique, the binary mobile phase (i.e. mobile 
phase was polar and the C18 stationary phase was non-polar was used).  
Elution conditions were optimized for both fresh and decomposed ascorbic acid.  
Compounds once eluted and separated are detected by the Series 200 EP Diode Array  
Detector. Optimized separation conditions are listed in table 2.1  
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Table 2.1. Represents working condition for HPLC. Mobile phase A consists of Methanol 
+ 0.001% trifluoracetic acid and mobile phase B consists of de-ionized water + 0.001% 
trifluoracetic acid.  
 Parameters Fresh ascorbic acid  Decomposed ascorbic acid  
Solvent condition  Mobile Phase A 90% and 
Mobile Phase B 10%  
Mobile Phase A 75% and  
Mobile Phase B 25%  
Flow Rate  1 ml/min  1 ml/min  
Detection Range  200-300 nm  200-450 nm  
Pressure  1000-1200 psi  1000-1200 psi  
  
 
    To make sure that mobile phase solvents are not interfering with the separation of 
compound we also ran a blank compound i.e. Mobile phase A (Methanol + TFA) solvent 
as a compound to be injected. Figure 6 represents HPLC data for blank sample.  
    Figure 2.4 shows that ascorbic acid is retained at time 1.407 minutes and no other 
compound being eluted from fresh ascorbic acid sample. Figure 2.5 shows two peaks at 
0.691 minutes and 1.198 minutes which surely suggests presence of more than one 
compound in decomposed ascorbic acid sample. A UV-Spectrum analysis was carried out 
on the two peaks obtained (seen in Figure 2.6) shows how the absorbance for the peaks 
changes over time.  
    Figure 2.6 shows that for the first peak absorbance is 0.05 and gradually changes 
as the peak descend and when the second peak ascends, the absorbance is 0.16 indicating 
a different compound and it reaches to 0.2 when the peak descend; Once again providing 
a clear evidence of presence of more than one compound.  
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Figure 2.4. HPLC for fresh ascorbic acid sample represents the elution time of the sample 
along with the absorbance. Concentration of fresh ascorbate used was 100 mm. 50µL of 
the sample was injected.  
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Figure 2.5. HPLC for decomposed ascorbic acid sample. Represents the elution time of the 
sample along with the absorbance. Concentration of decomposed ascorbate used was 100 
mm. 50µL of the sample was injected.  
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Figure 2.6. UV-SPECTRUM of the peaks obtained from decomposed ascorbic acid. 
Absorbance changes for the two peaks. From 0.06 for the first peak to 0.2 for the second 
peak. Indicating two different compounds.  
  
  
  
  
X axis: - Time in minutes 
Y axis: - Absorbance 
X axis: - Time in minutes 
Y axis: - Absorbance 
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Figure 2.7. HPLC for blank sample. Shows no compound coming out of the HPLC system. 
Indicating Mobile phase solvents do not interfere with the separation of decomposed 
ascorbic acid.  
2.4 3-D PRINTED DEVICE  
2.4.1 NEED FOR THE DEVICE  
In order to identify which component(s) in these 2 solutions (fresh and decomposed 
ascorbic acid) was responsible for initiating NO release from SNAP, a novel device was 
designed and used to couple the separation capacity of the HPLC with the direct NO 
measurement capability of chemiluminescence. Much of the earlier work done in the 
literature are just techniques used to separate compounds from decomposed ascorbic acid 
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and identify them. None of the work done to this point directly studied which of these 
compounds are responsible for NO release when in contact with RSNOs.   
2.4.2 SPECIFICATION OF THE DEVICE  
Device was printed by Dr. Joshua Pearce using an open source method of scientific 
hardware design [Pearce 2012; Pearce 2014; Baden 2015] [8] The main apparatus was 
augmented with a 3-D Printed Complex-Carbohydrate-Mixer, first developed by Brian 
Swanson and made available on Github [Swanson, 2014]. [9,10]. This device facilitates 
NO detection by allowing the compounds to mix and react with the small mixing chamber 
located at the center of the device. Released gases are detected by allowing them to pass 
through a filter which is a gas permeable membrane. The membrane is placed between the 
device and the 3-D printed cover, allowing the sampling of any NO generated when the 
eluent from the HPLC mixes with the stream of RSNO via chemiluminescence. Figure 2.10 
represents the 3-D printed device.  
  
  
  
   A       B  
  
Figure 2.8 CAD Design of the 3-D printed device.   
A: - Represents the actual device, left opening takes input from the syringe pump and right 
opening takes input from HPLC.  
  
Left  
Opening  
Right  
Ope ning  
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B: - Represents the cover of the Meshlab screen shot of STL of 3-D printed cover with 
mounting holes  
The 3-D printed parts can be manufactured in any fused filament fabrication (FFF) based  
3-D printer such as the open source RepRaps (self-replicating rapid prototypers)  
[Bowyer; Sells; Jones] [11,12,13]. The custom parts are 3-D printed in polylactic acid 
(PLA) or similar hard thermoplastic, which is chemically stable with the experiment. In 
this case, natural PLA was printed at 100% infill with 100 micron layers. Previous work 
that investigated the mechanical properties of PLA has found that these materials are 
optimal for strength [Tymrak; Wittbrodt] while also minimizing contamination from 
unknown pigments in commercial 3-D printing filament.   
  NO generated passes Through  
 
Figure 2.9 represents schematic flow of compounds for 3-D printed device.  
 
2.4.3 VALIDATING THE DEVICE  
To validate proper functionality of the device, experiments were performed that 
directly injected solutions of a known RSNO and known samples of agents that would 
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initiate NO release from the RSNO solution. Fresh 100mM ascorbic sample and SNAP 
were injected through the two openings on the left and the right side of the 3-D printed 
device using a syringe pump. Flow rate was set at 1ml/min. NO Analyzer input was 
connected to the Central opening on the 3-D printed plate placed above the gas permeable 
membrane. Figure 2.10 shows NO Release Profile of the fresh ascorbic acid sample. To 
setup a detection limit for the system this experiment was repeated 3 times with varying 
concentration of SNAP starting from 1mg and going down to 0.2mg (i.e. 1mg/50ml of de-
ionized water). Table 2.2 represents the compound of NO released by each sample.  
Table 2.2 Total amount of NO released by each sample.  
Samples  Concentration  Amount of NO released  
S1  1mg SNAP + 100mm  
Ascorbic acid  
4.07x10-9 moles  
S2  0.5mg SNAP + 100mm  
Ascorbic acid  
2.33x10-9 moles  
S3  0.2mg SNAP + 100mm  
Ascorbic acid  
6.62x10-11 moles  
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         Figure 2.10 Represents NO release profile of Samples S1, S2 & S3  
  
    The second part of the experiment, samples of 100mM decomposed ascorbic acid 
and SNAP (0.5mg/50ml of di-ionized water) were injected through the two openings. 
Decomposed ascorbic acid was obtained by allowing fresh ascorbic acid sample to 
decompose in ambient conditions for eight days. The NO analyzer input was connected to 
the central opening on the 3-D printed plate placed above the gas permeable membrane.  
Figure 2.11 shows the NO release profile of the decomposed ascorbic acid sample.  
  It can be clearly seen from the data that decomposed ascorbic acid releases twice 
the amount of NO compared to fresh ascorbic acid sample. Thus, validating that device can 
be used to integrate HPLC system directly with the NO analyzer. The difference will be 
that one of the inputs is from the HPLC system and the other using Syringe pump, instead 
of both coming from syringe pump as in case of the above experiments.  
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2.5 HPLC INTEGRATED WITH NO ANALYZER  
  Once the compounds had been separated via HPLC, the next task was to integrate it with 
the chemiluminecscne detector for NO with the system to prove that decomposed ascorbic 
acid generates more NO than fresh ascorbic acid. To integrate the two systems, we use the 
device 3-D Printed Device. Figure 2.11 shows a schematic representation of the integrated 
system.  
  Workflow of the setup is simple: waste coming out of the HPLC acts as one of the inputs 
for the bridge and the second input is SNAP which acts as an NO donor. The two 
compounds are allowed to react at the center of the “3-DPrinted Device”. A gas permeable 
membrane is placed over the central opening which is directly connected to the NO 
Analyzer. Waste from the reaction is collected into an empty vial. There is a Lag time 
between the compounds reaching the BRIDGE and the NO Generated.  
  
Figure 2.11 Schematic flow of the integrated system. Two inputs to the 3-D Printed device 
are from HPLC and syringe pump. NO Analyzer data is collected through an opening 
across the gas permeable membrane  
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Figures 2.12 Represent the amount of NO Released from the blank sample, Fresh and 
decomposed ascorbic acid. Spike in the NO profile for blank sample is due to the SNAP 
alone and lag time in HPLC compound reaching the 3-D Printed Device. The amount of 
NO released from the decomposed ascorbic acid is more than twice the amount released 
from fresh ascorbic acid. This proves that when ascorbic acid decomposes it release more 
NO than fresh ascorbic acid, which concludes that a new compound is formed when 
ascorbic acid decomposes.   
  
 Table 2.3 Represents Total NO released by blank sample, fresh and decomposed ascorbic 
acid  
Compounds  Total NO released ±(SD)  
Fresh ascorbic acid  170x10-12 (1.07x10-10) moles  
Decomposed ascorbic acid  350x10-12 (3.50x10-10) moles  
Blank sample  6.29x10-12 (6.29x10-12) moles  
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Figure 2.12 NO release profile for blank sample, fresh and decomposed ascorbic acid.   
2.6 CONCLUSION  
  UV-VIS Spectroscopy was used to identify the absorption wavelength of fresh and 
decomposed ascorbic acid. Once the detection wavelength was established it was used to 
setup a wavelength window for separation of decomposed ascorbic acid. HPLC separation 
technique helped to separate decomposed& fresh ascorbic acid.   
  Figure 2.5 shows the separation of decomposed ascorbic acid with retention time. 
Change in the absorbance from the UV-Spectra graph represents presence of more than 
one compound present. Once the separation was complete NO data was collected for both 
decomposed and fresh ascorbic acid by using 3-D Printed device as a medium to integrate 
HPLC with NO analyzer to obtain real time data.  
  Figure 2.12 represents the amount of NO released from decomposed ascorbic acid 
when it was separated using HPLC. Same procedure was also repeated using a blank, which 
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proves that it is actually decomposed ascorbic acid that causes more NO to be released as 
compared to Fresh ascorbic acid. The amount of NO released by decomposed ascorbic acid 
is almost twice the amount released by fresh ascorbic acid.  
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3. IDENTIFICATION OF NO RELEASING COMPOUND  
  Ascorbic acid is a well-known antioxidant and vitamin which is widely distributed 
in nature, and also part of our daily diet. Ascorbic acid is also known for its antioxidant 
property in both in vitro and in vivo. The initial step in ascorbic acid metabolism is 
conversion into dehydroascorbic acid (DHA); this process is reversible and is suspected to 
be responsible for its antioxidant properties. DHA is degraded to 2,3diketogulonic acid and 
then to over 50 species containing five or less carbons [2]. The complete mechanism of 
degradation is unknown due to the highly reactive and complex pathways available for 
decomposition [2]. Ascorbic acid is also known to react with RSNOs to produce NO. Much 
work has been done on studying degradation products of ascorbic acid, but the mechanism 
of decomposition under physiological conditions has not been elucidated. Gaston Vernin, 
et al. studied thermal degradation of ascorbic acid at 3000 C yielded furan derivatives and 
, β-unsaturated cyclic ketones with a fivemembered ring. Since ascorbic acid is a required 
part of our daily food cycle it makes it all the more important to identify its decomposition 
product(s) triggering NO release, since it is naturally present in our body.  
  There are three known mechanics of NO generation from S-nitrosothiols (RSNOs) 
[3]. Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then Cu+ 
reduces RSNOs to NO and produces disulfide bonds. Common species used to reduce Cu2+ 
to Cu+ are free thiolate ions and ascorbic acid. Ascorbic acid itself has been reported to 
directly interact with RSNOs when it is present at greater than millimolar concentrations 
to reduce RSNO to NO and produce free thiol groups. The mechanism of this reaction is 
not known [4]. The third known mechanism of NO generation from RSNOs is by means 
of photoinitiation. 
  Dasgupta and Smith published a study entitled “Kinetics and Mechanism of the  
Decomposition of S-Nitrosoglutathione (Type of RSNOs) by Ascorbic Acid and Copper  
Ions” [6]. The state that S-nitrosothiols severs as a good source of NO mainly due to the 
ease of cleavage of S-N bond which consequently produces NO. The reductive 
decomposition of the specific RSNO, S-nitrosoglutathione (GSNO) by ascorbic acid 
produced NO which was monitored both electrochemically and spectrophotometrically. 
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The rate of reaction and NO release occurs in an ascorbate concentration and pH dependent 
manner. There is little to no reaction at low pH (below 5.5). Reductive decomposition of 
GSNO by ascorbate in an aqueous solution was carried out in the presence of EDTA to 
suppress any copper catalysis.  
  Dasgupta and Smith proved that GSNO decomposition had a liner dependence on 
the concentration of ascorbate from 10-55mM. In their analysis.  they could only account 
for the 90% of ascorbate used initially when combining total ascorbate and DHA present 
initially, claiming that the lost 10% was probably due to “analytical error”. This suggests 
that ascorbic acid decomposes into different or additional products and it is possible that 
one of these products is an active agent that is responsible for the release of NO from 
RSNOs.  (i.e., more favorable redox potential and/or kinetics of electron transfer to react 
directly with RSNO).  
  
Figure 3.1 Comparison of NO generated from 0.227Mm SNAP solution in PBS at Ph 7.4 
[5]. 
  
  Figure 3.1 shows NO generated from 0.227 mM SNAP solutions in PBS at pH 7.4 
upon the addition of fresh ascorbate and the addition of the same amount of oxidized 
ascorbate from the same solution after 8 d of decomposition under ambient conditions 
using chemiluminescenc detection. After the first injection of ascorbate or oxidized 
ascorbate, the final concentration of ascorbate was 2.5 mM and 5 mM after the second 
injections. Clearly there is more NO generated from the oxidized ascorbate than from the 
fresh ascorbate, by nearly a factor of 10.  
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None of the work published to date has been able to identify the mechanism of 
ascorbic acid to directly decompose RSNOs nor have decomposition products of ascorbate 
been investigated as potential species that release NO. Correctly identifying the product or 
products that may be responsible for RSNO decomposition may provide us with new 
candidate material(s) for coatings on the implanted device and may also improve their 
performance in vivo and help mitigate host response. This study has developed a new 
experimental method to help separate the decomposition products which are responsible 
for NO release.  
    As previously discussed in chapter 1 the amount of NO generated from 
decomposed ascorbic acid is more than that produced by fresh ascorbic acid. This clearly 
indicates that it is not actually ascorbic acid but one its decomposition product which leads 
to increased production of NO.  
Ascorbic acid upon oxidation is converted into dehydro-L-ascorbic acid (DHA), 
which later is non-enzymatically converted to a variety of products [2]. These products are 
known as ascorbic cascade. We used high performance liquid chromatography (HPLC) 
with a photo diode array detector (PDA) along with Series 400 quaternary pump to separate 
the decomposed ascorbic acid. As concluded in Chapter 2 we did separate compounds from 
decomposed ascorbic acid and integrated it in real time with NO analyzer using the “3-D 
Printed device”. We concluded from the results that it is not actually ascorbic acid but one 
of the decomposition products of ascorbic acid that produces NO from RSNOs. Although 
HPLC separated some of the components of the complex mixture that resulted from the 
decomposition of ascorbic acid, the component(s) that eluted at 1.98 mins (Figure 2.7, 
Chapter 2) that cause release of NO need to be identified. There for MS analysis of this 
peak was carried out using a Thermo Finnigan LCQ Advantage Ion-Trap was the device 
used to run the Mass spectroscopy analysis.  
As stated in chapter 2, HPLC was carried out using PDA detector and series 400 
pump. Separation was achieved using C18 column. Mobile phase was methanol and 
deionized water each containing 0.01% trifluoracetic acid. Eluent was pumped at the flow 
rate of 1ml/min. The chromatographic data i.e. retention time, wavelength, absorbance was 
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obtained as contour maps through multichannel PDA detector, which covered a wavelength 
range of 200-450 nm. Elutes were examined by absorption spectrum, further 
characterization and identification of the compounds were done using Electron Spray 
Ionization technique was used during mass spectrometry.  
3.1 ASCORBIC ACID DECOMPOSITION CASCADE  
Once ascorbic acid is decomposed into DHA, it can then rapidly convert into a 
variety of transformation products possessing absorption maximum between 240 and 350 
nm. Eiji kimoto et al (2). Studied the decomposition cascade of ascorbic acid. Using 
electrochemical detection-HPLC analysis. Figure 3.2 shows the structures of compounds 
involved in this cascade. They suggested a possible decomposition pathway of DHA. DHA 
is easily delactonized into 2,3-diketo-L-gulonic acid(DKG). DKG undergoes isomerization 
to form the 6-membered R-345. DKG solution may also be subjected to decarboxylation 
to form L-xylosone (XLS) as reported by whiting and coggins. (1) Subsequently 
transformation produces various five-carbon.  
 
XLS is converted to Compound VI. Compound VI is dehydrated to from compound 
VIII, the unsaturated α- keto acid, which is further dehydrated to produce 2 Furoic acid 
(2FA) (compound XI) and/or 3OH2P (Compound XII) of the 2-pyrone form. As an 
alternative pathway XLS is converted to enediol form, Compound VII. Its aldehyde group 
is oxidized to carboxyl group which is lactonized to form EAsA. Intramolecular redox 
reaction of compound VII leads to rearrangement from the aldehydic to the carboxylic 
group and from the hydroxymethyl at the  
C (5) position to the methyl group, thus producing compound X. It undergoes ring 
closure to form MDT. Otherwise, the aldehydic group of compounds VII reamins intact. 
It dehydrated and reduced i.e. loss of oxygen to form compound IX of the structure. 
Compound IX is dehydrated to form FF of the furan form, or it is rearranged to form the 
bialdehydic structure as an unstable intermediate which undergoes ring closure easily to 
form RA.  
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Identification of the actual compound that initiated NO release form RSNOs is 
extremely important. If the identified compound is stable and non-toxic it could provide a 
means that initiate RSNO decomposition in polymeric materials or endogenously from 
RSNOs present in biological systems. For example, a polymer such as medical grade 
polyurethane doped with the reducing agent could be formulated such that when exposed 
to blood the active agent slowly leaches from the material, decomposing circulating 
nitrosothiols and preventing thrombus formation on the device.  
        
Figure 3.2 Represents structure of the 5-Carbon compounds involved in the cascade.  
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Figure 3.3 Possible reaction pathway for the transformation products of ascorbic 
acid [2].  
3.2 EXPERIMENTAL PROCEDURE FOR MASS SPECTROSCOPY  
Reagents and chemicals of highest grade was obtained from Sigma-Aldrich (St.  
Louis, MO, USA). Nitrogen gas was purchased from General Air Service and Supply 
(Denver, CO, USA).  DHA and 2FA were also purchased from Sigma-Aldrich. Methanol 
along with di-ionized water were used as solvent for mass spectroscopy in 50-50 % ratio.  
Thermo Finnigan LCQ Advantage Ion-Trap was used for mass spectroscopy.  
The Finnigan LCQ Advantage is an ion trap mass spectrometer. This instrument is 
capable of performing both single stage LC/MS a double stage LC/MS/MS. Sample 
solution is introduced to the mass spectrometer via loop injection. It uses electrospray 
ionization (ESI) ESI results in the generation of highly charged droplets directly from the 
infused solution. Multiply and/or singly charged analyte molecules desorb from the 
sprayed droplets and are sampled through the mass spectrometer for mass analysis. Rest of 
the equipment consists of quadruple ion trap where the ions are trapped followed by a 
photodiode array (PDA) detector. Compounds collected from HPLC separation were used 
an input samples for mass spectroscopy. 500µl of samples is injected, data is recorded for 
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11 minutes. After running each sample solution of methanol and de-ionized water is used 
for cleaning injector module. Once it is cleaned another sample with same amount is 
injected for analysis.   
 
3.3 DATA ANALYSIS FOR MASS SPECTROSCOPY 
Upon introducing the eluent from the HPLC peak of interest into the MS, the 
components were first ionized. The ions then travel to the mass analyzer and arrive at the 
different part of the detector according to the mass/charge ratio. After the ions make contact 
with the detector useable signals are generated and displayed on the computer. Yaxis is 
labelled as the relative abundance, which is actually the relative intensity. This is the 
intensity relative to the tallest peak in the spectrum with the tallest peak set to 100%. X-
axis is the mass divided by the charge ratio m/z. since the charge is always +1 with ESI, 
the m/z ratio always represent mass. All the data collected is in the positive ion mode since 
there were compounds detected in the negative ion mode.   
  First MS analysis was carried out on the HPLC separated compounds for 
decomposed ascorbic acid. Figure 3.3 represents MS data for HPLC separated decomposed 
ascorbic acid. Spectra show a number of peaks which suggests presence of multiple 
compounds. Each peak obtained from the HPLC separation was further broken down for 
full mass analysis. Compounds with m/z charge ratio higher than 550 m/z did not break 
down into smaller fragments. However, peak with 430.8 m/z ratio was further broken down 
to 158.9 m/z ratio. Using the ascorbic acid decomposition cascade as reference we 
suspected this peak to be either dimers of dehydroascorbic acid or 2-furoic acid keeping 
their molecular mass in account with either addition or donation of hydrogen ions. After 
narrowing it down to two compounds i.e. dehydro-ascorbic acid and 2-furoic acid we 
performed MS on these two compounds to see if we could find any overlap.   
Reference material 2-Furoic acid and Dehydro-ascorbic acid of highest purity was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) for testing NO release and perform 
mass spectroscopy to see if any compounds overlap with the existing data. Five different 
samples were prepared for both MS analysis and then as pure substances that would 
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directly initiate release of NO from SNAP measured in the chemiluminescence detector. 
Table 3.1 lists compounds selected for further testing suggested from MS analysis: -  
Table 3.1 Represents the compounds selected for testing along with their respective 
concentration.   
Compound I  2-furoic acid (2FA)  1mm   
Compound II  Dehydro-ascorbic acid  
(DHA)  
1mm  
Compound III  DHA + 2-furoic acid  1mm(DHA) 50% +  
1mm 2-FA (50%  
Compound IV  2-furoic acid + 
Ascorbic acid  
1mm (2FA) 50% +  
1mm Ascorbic acid 
50%  
Compound V  Ascorbic acid  1mm  
  
 
Table 3.2 Represents m/z ratio of each of the compound tested, it also includes a further 
breakdown of the m/z ratio which were possible.  
Compound  m/z ratio  m/z ratio (Further 
breakdown)  
HPLC separated 
decomposed ascorbic 
acid  
430.8  158.9  
2-Furoic acid  424.9  157  
DHA + 2FA  424.9  157  
Ascorbic acid  178    
Ascorbic acid + 2FA  Multiple peaks    
  
Mass spec analysis was performed on the HPLC separated compounds, to further 
identify the exact compound mass spec analysis was performed on all of the five 
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compounds listed in Table 3.1 to find any overlap with the HPLC separated compounds. 
2-Furoic acid had compound with m/z ratio of 424.9 which was found in decomposed 
ascorbic acid, i.e. compound with compound with 424.9 m/z broke down into 157m/z as 
seen in figure 3.5(Figure 3.5 shows mass spec data for 2-FA). So, did the combination of 
DHA + 2-FA losing a pair of hydrogen atoms, i.e. compound with m/z 424.9 which further 
broke down in to 157 m/z like that found in Figure 3.1(Figure 3.4 shows Mass spec data 
for DHA + 2FA). Since there is an overlap of m/z ratio from both 2FA and 2FA + DHA 
with the originally separated decomposed ascorbic acid it was concluded that either 2FA 
or DHA is one of the decomposition products of the ascorbic acid responsible for the large 
amount of NO release. Further analysis on the compound i.e. 2FA + Ascorbic acid shows 
no overlap in m/z ratio with the HPLC separated decomposed ascorbic, which concludes 
that ascorbic acid suppresses the presence of 2-furoic acid and forms a complex mixture, 
that might be one of the reasons why ascorbic acid produces a lower amount of NO as 
compared to 2 furoic acid. (Figure 3.9 & 3.10 describes it in more detail)  
 
Figure 3.5 represents MS data for 1mm 2-furoic acid. It also showed presence of 
multiple peaks. Peaks with m/z charge ratio above 550 did not show any break down 
fragments in full mass analysis of the spectrum, however the peak with m/z ratio 424.9 was 
further broken down into peak with m/z ratio 157. Which indicates similar compound as 
seen in HPLC separated decomposed ascorbic acid.  
Similarly Figure 3.6 represents MS data for the combination of DHA and 2-FA 
(1mm). Data reported presence of the same compound with m/z ratio of 424.9 which could 
be further broken down into fragment of m/z ratio 157.   
Figure 3.7 represents MS data for fresh ascorbic acid sample (1mM). Molecular 
mass of ascorbic acid is 176 g/mol so the m/z ratio should be 177 with the addition of one 
hydrogen atom, which is seen in the figure 3.5 ascorbic acid with peak of m/z ratio 177.  
Figure 3.8 represents MS data for the combination of fresh ascorbic acid with 
2furoic acid. Data showed no overlap with any of the peaks seen earlier, which lead us to 
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believe that ascorbic acid suppress the presence of 2-furoic acid to form some other 
compounds.  
  
  
Figure 3.4 Mass Spectroscopy data after HPLC Separation for Decomposed Ascorbic acid. 
Left side represents spectrum view over the range of 200 – 1000 m/z ratio. Right side 
represents Further breakdown of 430.8 m/z ratio.   
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Figure 3.5 Mass Spectroscopy data for 2-Furoic acid. Left side represents spectrum view 
over the range of 200 – 2000 m/z ratio. Right side represents Further breakdown of 424.9 
m/z ratio.   
  
Figure 3.6 Mass Spectroscopy data for DHA + 2FA. Breakdown of 424.9 m/z ratio.  
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Figure 3.7 Mass Spectroscopy data for Fresh ascorbic acid sample.  
  
  
Figure 3.8 Mass Spectroscopy data for Fresh ascorbic acid + 2-furoic acid in 50-50% ratio. 
NO overlap of compounds for comparing with decomposed ascorbic or 2-furoic acid mass 
spec data.  
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3.4 DETERMINATION OF NO GENERATION  
To calculate the amount of NO release from each compound we designed the 
folloing expeperiemnt. Nitrogen was used as a sweeping gas for all the four analyses. 
SNAP crystals of 0.8 mg were used in each experiment. SNAP was placed in a dark vial 
and connected to the NO analyzer with the sweeping gas. After 10 minutes, 2ml of 
Phosphate Buffer Saline (PBS) of concentration mixed with Chelex 100 is added to the 
SNAP crystals. This causes NO release because of reaction between trace metal 
contaminants and SNAP. After a period of 1 hour we injected the one of the four 
compounds listed above recording the NO profile, as the readings reaches a plateau we 
inject 1mm CuCl2 to it in order to initiate complete decomposition of the SNAP remaining 
in solution.   
3.5 DATA ANALYSIS FOR NO ANALYZER  
Each set of experiments was performed in triplicates. Dark colored vial was used 
to avoid NO release through photoinitiation. Chelex 100 is used a chelating agent for 
purification of compounds via ion exchange. Copper chloride was added in the end just to 
show that system still contains nitric oxide.  
Initial readings show zero nitric oxide released for first 10 mins which indicates 
that SNAP crystals used are stable. Upon addition of PBS it releases nitric oxide. Once the 
PBS readings reaches a plateau we inject the compound of interest. Data shows that 2-
Furoic acid releases maximum amount of NO i.e. 900 PPB. When ascorbic acid is 
combined with 2-furoic acid the amount of NO released is almost 1/3 in comparison to that 
intuited from pure 2-furoic acid.  
Table 3.3 Represents Amount of NO released from 2-furoic acid, dehydroascorbic acid and 
fresh ascorbic acid  
Compounds  Amount of NO Released  
2 Furoic acid  101x10-08 moles  
Dehydroascorbic acid  1.01x10-8 moles  
Fresh Ascorbic acid  28.2x10-08moles  
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Table 3.4 Represents Amount of NO released from 2-furoic acid + ascorbic, 
dehydroascorbic acid + ascorbic acid and fresh ascorbic acid  
Compounds  Amount of NO Released  
2 Furoic acid + ascorbic acid  15.1x10-8 moles  
Dehydroascorbic acid + ascorbic  11.4x10-8 moles  
2 furoic acid  30.4x10-8 moles  
  
Figure 3.9 shows a direct comparison between the NO released from the 2-Furoic 
acid, Dehydroascorbic acid and Fresh ascorbic acid. Last spike in the Figure is due to 
injection of Copper Chloride which reacts with SNAP to give huge amount of NO.  
From this data, it is very suggestive that 2-furoic acid or dimers of this compound 
are responsible for initiating NO release from RSNOs.  
 
Figure 3.9 Direct comparison between 2-furoic acid, Dehydroascorbic acid and fresh 
ascorbic acid. 2-furoic acid releases highest amount of NO.  
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Figure 3.10 Direct comparison between 2-furoic acid, dehydroascorbic acid & fresh 
ascorbic acid. 2-furoic acid releases highest amount of NO.  
  
3.6. CONCLUSION  
  The goal of the project was to identify the compound responsible for production of 
NO. In order to do that there was a need to study and identify decomposition products of 
ascorbic. Compound separation was done using HPLC. Once the compounds were 
separated real time NO analysis was carried out on both decomposed ascorbic acid and 
fresh ascorbic acid taken from HPLC using 3-D printed device as a medium. It was 
concluded that decomposed ascorbic acid produces more NO compared to fresh ascorbic 
acid. Next step was to identify the compounds present in the decomposed ascorbic acid and 
then test those compounds separately for NO generation. Identification of compounds were 
carried out using mass spectroscopy.  
  Based on the MS data and the testing of pure compounds from the ascorbic acid 
decomposition cascade, the potential compounds responsible for the release of NO from 
RSNOs was narrowed down to either DHA or 2-FA. All the compounds tested showed 
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some amount of NO released, but 2-FA, by itself, showed almost three times the amount 
of NO released compared to other compounds. Combination of both fresh ascorbic acid 
and 2-FA release NO similar to that of the combination of DHA and 2-FA which indicates 
that the ascorbic acid suppresses the presence of 2-furoic acid in the system, similar to be 
said for DHA since it is an immediate decomposition product of ascorbic acid.  
  Thus, both the MS data where peak of m/z i.e. 424.9 ratio of the 2-furoic acid 
coincides with the peak of the HPLC separated decomposed ascorbic acid. Furthermore, 
the NO data showing maximum amount of NO released is from 2-FA out of the 
combination of all the compounds. Therefore, it is likely that 2-furoic acid is the agent that 
causes NO release instead of high concentrations of ascorbic acid.  
  2-furoic acid is a carboxylic acid, consisting of a five-membered aromatic ring. It 
is an organic product most widely used in food products as a preservative and a flavoring 
agent. 2-furoic acid is no-toxic. Whole goal of the project was to eventually develop a 
polymer with 2-furoic acid in its backbone, which can be coated on a medical device upon 
contact with blood it leaches and reacts with biological RSNOs to produce NO.  
Since 2-furoic acid is potentially used in many of the food products so the human body is 
not subjected to any toxic products.  
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4. CONCLUSION AND FUTURE DIRECTIONS  
With the increasing number of illness which cannot be tackled with medication 
alone there is an increasing need for implantable medical devices. Studies for improving 
the quality and design of implantable devices has been carried out since early 1960s and 
tremendous progress has been made in miniaturization of reliable devices that are capable 
of monitoring and improving physiological function in vitro. There is still a stark crop in 
performance when these devices are actually placed in the complex and dynamic in vivo 
environment. Understanding the host response is extremely important in development of 
implantable devices. One of the emerging solution is nitric oxide (NO) releasing polymer 
coatings on   implanted medical devices. The focus of the work described herein is to 
identify the NO generating decomposition product of ascorbic acid.  
Nitric oxide is potentially viable option to help control the coagulation cascade and 
wound healing responses, i.e. driving pathways that determine ultimate host response. NO 
has a diverse array of functions in vivo including help controlling the blood vessel tone and 
adhesion receptor expression. NO is also a potent inhibitor of platelet aggregation and 
activation. NO is also involved in endothelium cell and smooth muscle cell proliferation; 
it has a direct role in destruction of bacteria during phagocytosis by macrophages. Vascular 
endothelium cells are estimated to generate NO flux of 1.0-4.0 x 10 -10 mol·cm-2 min-1 
continuously and is the primary basis for the non-thrombogenic properties of the vascular 
endothelium, surface which elicits normal host response (i.e., the coagulation cascade is 
not activated) despite constant contact with precursor molecules to the intrinsic coagulation 
cascade. The endogenous NO supply diffuses into the lumen of the blood vessels and 
smooth muscles cells that surrounds all the arteries where it plays an important role in 
preventing platelet activation in healthy blood vessels.  
The innate physiological functions of NO make it a strong candidate for improving 
the biocompatibility of the implanted devices. NO releasing sensors will be capable of 
controlling both platelet adhesion and activation along with minimizing vasocontraction. 
NO releasing subcutaneous implanted sensors have been shown to increase blood flow to 
the sensor surface, increase transfer of analyte, reduce bacterial adhesion and reduce 
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fibrous encapuslation. Because the half-life of NO in the biological system is 0.5-1.8ms, 
the NO generated should not create any systemic effects.  
   There are three known mechanics of NO generation from S-nitrosothiols  
(RSNOs). Copper mediated decomposition in which Cu2+ is first reduced to Cu+ and then 
Cu+ reduces RSNOs to NO. Common species used to reduce Cu2+ to Cu+ are free thiolate 
ions present as impurities in RSNO solutions and ascorbic acid. Ascorbic acid itself has 
been reported to directly interact with RSNOs when it is present at greater than millimolar 
concentrations to directly reduce RSNO to NO and produce free thiol groups. The 
mechanism of this reaction is not known. The third known mechanism of NO generation 
from RSNOs is by means of photoinitiation.  
The work presented here focused on elucidating the species responsible forNO 
generation from ascorbic acid. Literature states that ascorbic acid when reacts with RSNOs 
it releases NO if present in more than millimolar concentration but we have shown that it 
is not actually ascorbic acid that causes NO release, rather a product that results from 
ascorbic acid decomposition under ambient conidtions . When ascorbic acid decomposes, 
it produces a complex mixture, it is one of these compounds that is actually responsible for 
the NO generation. Main goal of this project was to study the decomposition products of 
ascorbic acid and identify the compound responsible for generating NO.  
UV-VIS spectroscopy was used to identify the absorption wavelength for both fresh 
ascorbic acid and decomposed ascorbic acid. Data suggests that peak absorption 
wavelength of ascorbic acid is 263nm which is consistent with the literature.  
Decomposed ascorbic acid showed several peaks with consistent change of absorbance. 
Additionally, the absorbance of the ascorbic acid peak at 263nm is reduced in intensity 
from 0.56 to 0.25 after 8 days of passive decomposition, indicating a significant loss of 
parent compound. This confirms that decomposition products of ascorbic acid are present 
in substantial quantities in the solution. The peaks resulting from these compounds have 
absorbance maximum ranging from 200 – 400 nm. This information was vital because it 
will help setup up the detection range for HPLC while physically separating these 
compounds.  
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HPLC system was used for separation of these decomposition compounds. Under 
the isocratic separation conditions utilized, ascorbic acid has a retention time 1.407 minutes 
and no other compound being eluted from fresh ascorbic acid sample. Decomposed 
ascorbic acid showed two peaks at 0.691 minutes and 1.198 minutes which surely suggests 
presence of more than one compound in decomposed ascorbic acid sample. A UV-
Spectrum analysis was carried out on the two peaks obtained which showed how the 
absorbance for the peaks changes over time. Th UV-Vis spectrum obtained from the diode 
array detector in the HPLC system showed that for the first peak absorbance is 0.05 and 
gradually changes as the peak descend and when the second peak ascends, the absorbance 
is 0.16 indicating a different compound and it reaches to 0.2 when the peak descends; Once 
again providing a clear evidence of presence of more than one compound.  
    To identify which component(s) in these 2 solutions (fresh and decomposed 
ascorbic acid) was responsible for initiating NO release from SNAP, a novel device was 
designed and used to couple the separation capacity of the HPLC with the direct NO 
measurement using NO analyzer. NO analysis was performed on Fresh ascorbic acid, 
decomposed ascorbic acid and a blank sample. The amount of NO released from the 
decomposed ascorbic acid is more than twice the amount released from fresh ascorbic acid.  
This proves that when ascorbic acid decomposes it release more NO than fresh ascorbic 
acid, which concludes that a new compound is formed when ascorbic acid decomposes.   
Table 4.1 Represents Total NO released by blank sample, fresh and decomposed ascorbic 
acid  
Compounds  Total NO released ±(SD)  
Fresh ascorbic acid  170x10-12 (1.07x10-10) moles  
Decomposed ascorbic acid  350x10-12 (3.50x10-10) moles  
Blank sample  6.29x10-12 (6.29x10-12) moles  
 
  Next step was to identify the compound responsible for NO release. Mass 
Spectroscopy was used for identifying decomposition product of ascorbic acid. Mass 
spectrum of a sample is a pattern representing the distribution of ions by mass (more 
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correctly: mass-to-charge ratio) in a sample. First MS analysis was carried out on the HPLC 
separated compounds for decomposed ascorbic acid. Spectrum showed number of peaks 
which suggests presence of multiple compounds. Each peak was further broken down for 
full mass analysis.  
 Compounds with m/z charge ratio higher than 550 m/z (mass by charge ratio) did 
not break down into smaller fragments. However, peak with 430.8 m/z ratio was further 
broken down to 158.9 m/z ratio. Using the ascorbic acid decomposition cascade as 
reference we suspected this peak to be either dimers of dehydroascorbic acid or 2-furoic 
acid keeping their molecular mass in account with either addition or donation of hydrogen 
ions. After narrowing it down to two compounds i.e. dehydro-ascorbic acid and 2-furoic 
acid we performed MS on these two compounds to see if there was an overlap.   
 Reference material 2-Furoic acid and Dehydro-ascorbic acid of highest purity was 
purchased for testing NO release and perform mass spectroscopy to see if any compounds 
overlap with the existing data.  
Table 4.2 lists compounds selected for further testing suggested from MS analysis:  
Compound I  2-furoic acid (2FA)  1mm   
Compound II  Dehydro-ascorbic acid  
(DHA)  
1mm  
Compound III  DHA + 2-furoic acid  1mm(DHA) 50% +  
1mm 2-FA (50%  
Compound IV  2-furoic acid + 
Ascorbic acid  
1mm (2FA) 50% +  
1mm Ascorbic acid 
50%  
Compound V  Ascorbic acid  1mm  
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Table 4.3 represents the compounds selected for testing along with their respective 
concentration.   
Compound  m/z ratio  m/z ratio (Further 
breakdown)  
HPLC separated 
decomposed ascorbic 
acid  
430.8  158.9  
2-Furoic acid  424.9  157  
DHA + 2FA  424.9  157  
Ascorbic acid  178    
Ascorbic acid + 2FA  Multiple peaks    
  
Table 3.2 Represents m/z ratio of each of the compound tested, it also includes a 
further breakdown of the m/z ratio which were possible.  
2-Furoic acid had compound with m/z ratio i.e.424.9 which was found in 
decomposed ascorbic acid i.e. compound with 424.9 m/z broke down into 157m/z. So, did 
the combination of DHA + 2-FA losing a combination of hydrogen atoms i.e. compound 
with m/z 424.9 which further broke down in to 157 m/z. Since there is an overlap of m/z 
ratio from both 2FA and 2FA + DHA with the originally separated decomposed ascorbic 
acid it was concluded that either 2FA or DHA is one of the decomposition product of the 
ascorbic acid responsible for the large amount of NO release. Further analysis on the 
compound i.e. 2FA + Ascorbic acid shows no overlap in m/z ratio with the HPLC separated 
decomposed ascorbic, which concludes that ascorbic acid suppresses the presence of 2-
furoic acid and forms a complex mixture, that might be one of the reasons why ascorbic acid 
produces less amount of NO as compared to 2 furoic acid.  
Last step was to perform NO analysis on these compounds to provide definitive 
evidence that 2-furoic acid is the actual compound that causes NO release. Data showed 
that 2-Furoic acid releases maximum amount of NO i.e. 1.01x10-6 moles. When ascorbic 
acid is combined with 2-furoic acid the amount of NO released is almost 1/3 in comparison 
to that intuited from pure 2-furoic acid. From this data, it is very suggestive that 2-furoic 
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acid or dimers of this compound are responsible for initiating NO release from RSNOs. 
Therefore, it is likely that 2-furoic acid is the agent that causes NO release instead of high 
concentrations of ascorbic acid.  
 For the scope of the experiments a very basic design of a 3-D printed device was 
created, which functioned sufficiently under these initial conditions. For future work, the 
3-D printed device should be optimized i.e. the size and shape of the reaction chamber,the 
angles for the incoming solutions into the reaction chamber, the dimensions of the channels 
into the reaction chamber. These optimizations should make the device generally more 
applicable to other potential HPLC separations coupled to gas reactant products. 
  2-furoic acid is a carboxylic acid, consisting of a five-membered aromatic ring. It 
is an organic product most widely used in food products as a preservative and a flavoring 
agent. 2-furoic acid is no-toxic. Whole goal of the project was to eventually develop a 
polymer with 2-furoic acid in its backbone, which can be coated on a medical device upon 
contact with blood it leaches and reacts with biological RSNOs to produce NO. Since 2-
furoic acid is potentially used in many of the food products so the human body is not 
subjected to any toxic products. Because this a simple compound that is stable, there are a 
wide variety of different conditions in which it may be used to create NO generating 
materials and surfaces. 
